Skip to main content
Premium Trial:

Request an Annual Quote

UMBI Spins Out Proteomics Company

NEW YORK (GenomeWeb News) – The University of Maryland Biotechnology Institute said Monday that it has spun out a proteomics venture that will commercialize protein characterization and quantification technology.

The new Rockville-based company, called Omic Biosystems, will market a technology called DiART (deuterium (2H) isobaric amine reactive tags) that uses protein tagging designs coupled with sample preparation technology for use in large-scale mass spectrometry proteomics studies.

Omic Biosystems CEO and Co-founder Feng Tao said in a statement that the company will "help solve important bottleneck problems in the field of proteomics."

"The immediate market impact of this technology is its utility in biomarker discoveries," UMBI's Director of Technology Transfer and Commercialization, Jonathan Gottlieb, said in a statement. "Its broader impact will facilitate the translation of genomic and proteomic information into relevant clinical information that can be applied to new drug discovery and clinical diagnostics."

The DiART technology was developed at UMBI's Center for Advanced Research in Biotechnology in the lab of UMBI Assistant Professor and Omic Biosystems' Co-founder Shuwei Li.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more